IM Cannabis Files 3:1 Share Consolidation to Defend Nasdaq Listing
The Israel-focused cannabis operator will fold every three common shares into one, a reverse-split move aimed at keeping its U.S. exchange listing alive.

Colorful stock market board displaying various company stock performances and trends.
IM Cannabis puts a 3:1 reverse split on the table to stay on Nasdaq
IM Cannabis Corp. will consolidate its common shares at a ratio of one post-consolidation share for every three outstanding, according to a company release dated November 19, 2026.
The company operates across Israel and Germany and reports from Vancouver and Glil Yam, Israel. It framed the consolidation as an effort to maintain its Nasdaq listing. The shares carry no par value. The release, in the portion available to CannIntel, didn't specify an effective date or the exact number of shares outstanding before and after the change.
That's the honest summary. Here's the read.
A reverse split is a listing-defense tool, not a growth strategy
Companies use share consolidations to lift a per-share price back above exchange minimums, and Nasdaq's continued-listing standards center on a $1.00 minimum bid price.
The mechanics are simple. Three shares become one, the quoted price roughly triples on paper, and the market capitalization stays the same on day one. Nothing about the underlying business changes. Not a dollar of revenue, not a point of margin.
My thesis: this is a survival move, and the market will judge it on what comes after the split, not the split itself. The history of micro-cap reverse splits is unkind, since prices often drift back down once the cosmetic lift fades, and that's how serial consolidators land in the compliance penalty box. A 3:1 ratio is also on the modest side. A company confident it needed a durable fix might have picked a steeper ratio to build a bigger cushion above $1.00. Three-to-one buys room. Not a lot of it.
The cannabis small-cap squeeze is the real story
IM Cannabis sits in a cohort of U.S.-listed cannabis names whose share prices have been ground down by capital scarcity, federal illegality, and thin institutional demand.
Plant-touching operators can't access the deep pools of capital that fund other sectors. Many rely on dilutive equity raises, convertible debt, or asset sales to stay solvent, and each of those tends to push share counts up and prices down. The reverse split is the usual end of that chain.
Israel-based and international operators face an extra wrinkle. Their revenue sits in shekels and euros while their listing sits in a U.S. dollar market. Investors who want cannabis exposure have plenty of U.S. multi-state operators to choose from, and niche geography is a hard sell to generalist funds. For context on how these compliance fights play out across the sector, see the CannIntel topic hub on cannabis stock listing compliance.
What shareholders and operators should watch
The consolidation resets the optics, but the durable test is whether IM Cannabis can hold the post-split price through its next quarterly cycle.
Three things matter from here:
- The effective date and the final post-consolidation share count, which determine how much headroom the company actually gains.
- Whether Nasdaq issues or closes out any deficiency notice tied to the bid price requirement.
- Any follow-on financing, since a fresh equity raise right after a reverse split can erase the price lift quickly.
Retail holders should also expect fractional-share handling and brokerage adjustments. Those mechanics vary by firm and can catch smaller holders off guard.
Compliance headroom isn't a turnaround. Investors tend to price the difference fast, and the first few weeks of trading after a consolidation often tell the story. If volume thins out and the bid wanders back toward the minimum, the split will have bought time and little else.
The shell-game risk deserves a plain mention. A company can keep a listing alive through repeated consolidations while the business underneath keeps shrinking. That outcome serves no one, least of all the holders who stay.
The next signal: the effective-date filing and the first full trading week afterward. If the post-split price can't clear $1.00 with room to spare, a second compliance notice is the likely next chapter.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business

California cannabis sales rebound a year after tax hike repeal
More than a year after lawmakers killed a short-lived excise increase, California retail sales are climbing again, but the recovery leaves a harder question about how much ground the state lost.

Grand Rapids Scraps Municipal Dispensary Build, Eyes Lease
The northern Minnesota city abandoned plans to construct its own cannabis storefront and will pursue leased space, according to KAXE.

Mile High Labs Files Type II DMF #044151 With FDA for CBD Isolate
The Loveland, Colo., ingredient maker opened a confidential FDA regulatory file on its CBD isolate, a supply-chain credential aimed at pharmaceutical buyers.
More from the newsroom

Charlotte's Web Urges Congress to Replace Section 781 Hemp Ban
The hemp CBD pioneer is asking lawmakers to swap Section 781's sweeping restrictions for enforceable standards that target delta-8 THC and protect children.

Companies Warn New DEA Policy Imperils Medical Marijuana Markets
Law360 reports that cannabis companies say a new DEA policy threatens state medical marijuana markets, though the underlying policy text was not available to CannIntel.

Texas Gov.-elect Hinojosa favors repealing 'Death Star bill'
Houston Public Media reports Gina Hinojosa backs repeal of the so-called 'Death Star bill,' a stance that could reshape Texas hemp and THC policy if she acts on it.